hospitalised
[용어속성] abnormalities
Bloodstream Infection by Saccharomyces cerevisiae in Two COVID-19 Patients after Receiving Supplementation of Saccharomyces in the ICU
Case Report
[키워드] Saccharomyces
acute respiratory distress
ARDS
Aspergillus
bloodstream
caused
Co-infections
complications
coronavirus disease
COVID-19
critical condition
critically ill patients
dysregulation
element
fungaemia
Fungal infection
hospitalised
ICU
immune system
Immunocompromised
immunological
Infection
infections
intensive care unit
invasive
morbidity and mortality
occur
organism
pandemic coronavirus
Patient
patients
Probiotic
reported
Saccharomyces cerevisiae
SARS-CoV-2
severe COVID-19
syndrome
[DOI] 10.3390/jof6030098 PMC 바로가기 [Article Type] Case Report
[DOI] 10.3390/jof6030098 PMC 바로가기 [Article Type] Case Report
Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study
Research article
[키워드] 95% CI
acute respiratory syndrome
Anticoagulants
Antigen
association
Asymptomatic
Benign
biochemical marker
Biomarker
CD40 ligand
clinical outcomes
Coagulation factors
Coagulopathy
Comparator group
complications
Concentration
Control
controls
coronavirus
correlated
correlation
COVID-19
Critical
cross-sectional
death
determine
elevated
Endothelial cell
endotheliopathy
Enzymes
Evidence
Factor
fibrinolytic
finding
funding
greater
hazard ratio
hematology
hospital
hospital discharge
hospitalised
ICU
ICU patient
ICU Patients
IMPROVE
Injury
intensive care
involved
Kaplan–Meier analysis
laboratory result
laboratory-confirmed
likelihood
marker
mitigate
Mortality
non-critically ill patient
non-hospitalised
non-ICU
non-ICU patients
outcome
P-selectin
Pathogenesis
Patient
patients
patients with COVID-19
platelet activation
previous study
progression
recruited
significantly
suggested
supported
survival
thrombotic
vWF
was used
with COVID-19
[DOI] 10.1016/S2352-3026(20)30216-7 [Article Type] Research article
[DOI] 10.1016/S2352-3026(20)30216-7 [Article Type] Research article
Treatment and preliminary outcomes of 150 acute care patients with COVID-19 in a rural health system in the Dakotas
Short Paper
[키워드] Administered
administration
adverse effect
arrhythmia
Care
clinical trial
Cohort
Community
convalescent plasma
coronavirus
Corticosteroids
COVID-19
disease severity
Efficacy
expired
Healthcare system
hospital
hospital discharge
hospitalised
Hydroxychloroquine
hydroxychloroquine plus azithromycin
majority
outcome
outcomes
Patient
patients with COVID-19
pharmacological treatment
Population
QT interval
regimen
resource
risk
Rural health
SARS-CoV-2
Spread
subsequent
survived
therapeutic anticoagulation
therapeutic option
Tocilizumab
treat
treated
Treatment
[DOI] 10.1017/S0950268820001351 PMC 바로가기 [Article Type] Short Paper
[DOI] 10.1017/S0950268820001351 PMC 바로가기 [Article Type] Short Paper
Chinese medicine for COVID-19 A protocol for systematic review and meta-analysis
3800
[키워드] 95% CIs
95% confidence interval
adverse effect
Analysis
appear
article
Asia
asymptomatic infection
cause
CBM
Chest CT
China
Chinese
Chinese medicine
CIs
CNKI
Cochrane Library
Consensus
continuous variable
Controlled trial
Coronavirus disease 2019
COVID-19
database
death
disagreement
disease
East
Efficacy
Efficacy and safety
Evidence
Handbook
hospitalised
include
Infrastructure
journal
literature
mean difference
Meta-analysis
Mild
Novel coronavirus
Nucleic acid detection
Odds ratio
outbreak
outcome
participant
Patient
performed
Placebo
Pneumonia
protocol
recruited
reported
resolved
Respiratory disease
Respiratory failure
Respiratory illness
Respiratory samples
Result
review
risk
risk of bia
Risk of bias
SARS-COV-2 infection
Science
searched
severe viral pneumonia
Spread
systematic review
technique
therapeutic agents
treat
Treatment
upper respiratory tract
variable
VIP
virus
with COVID-19
Wuhan, China
[DOI] 10.1097/MD.0000000000020660 PMC 바로가기 [Article Type] 3800
[DOI] 10.1097/MD.0000000000020660 PMC 바로가기 [Article Type] 3800
AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial
AGILE-ACCORD: COVID-19 치료를 위한 여러 후보 약제의 최적 용량, 안전성 및 효능을 결정하기 위한 무작위, 다기관, 원활한, 적응 I/II상 플랫폼 연구: 무작위 플랫폼에 대한 연구 프로토콜의 구조화된 요약 재판
Letter
[키워드] 9-point ordinal scale
acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
adaptive
added
Adult patients
Adverse
adverse events
agent
Anti-viral treatment
approval
Bayesian
Blinding
candidate
Candidates
clinical
Clinical improvement
cloud
Cohort
cohorts
Combination
Common Terminology Criteria
Community
community setting
comparator
contributing to
coronavirus
COVID-19
COVID-19 infection
CST
cytokine
cytokine release
death
defined
determine
disease
dissemination
dose
EDC
Efficacy
Efficacy and safety
element
eligibility criteria
eligible
England
EudraCT
evaluated
expected
for inclusion
futility
GRADE
group
hospitalised
hospitalised patient
Hospitalization
in some
include
Infection
intubation
Ireland
laboratory-confirmed
later phase
limit
Mask
Master protocol
mechanical ventilation
mechanism
mechanism of action
multi-arm
multicentre
Multiple
nasal prongs
non-invasive ventilation
North
number
objective
open
Open-label
opens
optimal dose
Ordinal Scale
organ
Other
outcome
oxygen
oxygen saturation
oxygen)
participant
Patient
patient population
patients
peripheral capillary
Peripheral capillary oxygen saturation
phase
Phase I/II
Placebo
platform
Platform study
Platform trial
Population
Prevent
progression of disease
promise
protocol
randomisation
randomised
Rave
recruited
recruitment
Regulatory
required
respiratory
Safety
Sample size
SARS-CoV-2
SARS-COV-2 infection
seamless
setup
severe acute respiratory syndrome Coronavirus
severe disease
shown
SOC
Specific
Stage
Standard
Standard of care
status
Study protocol
the WHO
toxicities
Toxicity
Treatment
treatment of COVID-19
Trial
Trial registration
Ventilation
Viral
Viral load
viral replication
website
WHO
working
[DOI] 10.1186/s13063-020-04473-1 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04473-1 PMC 바로가기 [Article Type] Letter
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
Research article
[키워드] 95% CI
acute respiratory syndrome
addition
Admission
admitted to ICU
age
Analysis
Cancer
Cardiopulmonary
Chemotherapy
chronic obstructive
clinical
Clinical characteristics
Clinical outcome
Cohort
cohort study
collaboration
collected
Comorbidities
Comorbidity
composed
consecutive patient
Cooperative
coronavirus
country
Course
COVID-19
COVID-19 diagnosis
COVID-19 in patient
criteria
cross-sectional
death
demographics
died
eight
eligible
epithelial
feature
finding
Follow-up
funding
General population
global pandemic
group
high mortality
high mortality rate
histology
hospitalised
hypertension
ICU admission
increased risk
Infection
intensive care
International
Laboratory
lung cancer
Lung imaging
majority
median age
medical record
Mortality
multicentre
multivariable analysis
multivariable logistic regression
Neoplasms
neuroendocrine
Odds ratio
Older
Older age
outcome
pandemic
Patient
patient data
patients
Patients with cancer
patients with COVID-19
performance status
Pneumonia
pulmonary disease
receiving
reduced
RT-PCR
SARS-CoV-2
Sex
smoker
smoking
smoking status
suggested
susceptible
Symptom
Symptoms
therapeutic options
therapy
Thoracic
Thoracic malignancies
Thoracic malignancy
thought
thymic
Treatment
Tumours
univariable
were measured
WHO
with COVID-19
[DOI] 10.1016/S1470-2045(20)30314-4 [Article Type] Research article
[DOI] 10.1016/S1470-2045(20)30314-4 [Article Type] Research article
A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam
Study Protocol
[키워드] 24 hours
Can
cause
caused
Chloroquine
city
clinical trial
control arm
Controlled trial
Coronaviruses
COVID
COVID-19
defined
detect
effective
evaluate
exclusion criteria
field
Ho Chi Minh
hospital
hospitalised
hypothesise
Infection
intervention arm
Loading dose
malaria
management
morbidity and mortality
multi
nine
Novel coronavirus
open label
outcomes
Parallel Arm
Patient
patients with COVID-19
people with COVID-19
pilot study
positive
Prevent
primary endpoint
randomised
randomised clinical trial
randomization
Randomized
randomized trial
recruit
Respiratory disease
resulting
RT-PCR
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 RNA
Standard of care
Swab
swabs
therapeutic
Tolerability
treat
Treatment
Trial
Vaccine
Vietnam
viral clearance
Viral load
viral replication
[DOI] 10.12688/wellcomeopenres.15936.1 PMC 바로가기 [Article Type] Study Protocol
[DOI] 10.12688/wellcomeopenres.15936.1 PMC 바로가기 [Article Type] Study Protocol
Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] 1:1
7-point ordinal scale
accelerate
activities
activity
acute respiratory syndrome
adaptive
addition
administration
Admission
airway
Akershus
allocation sequence
Analysis
anticipated
approach
automatically
baseline
Biochemistry
Biomarker
blinded
Blinding
Blood
C-reactive protein
cardiac troponin
Chloroquine
clinical
Clinical outcome
Clinical practice
clinical status
clinical symptom
collected
condition
coronavirus
coronavirus disease
COVID-19
Culture
database
Department
disease
dissemination
early treatment
element
Endpoint
examined
excluded
extracorporeal membrane oxygenation
Good
harmonization
hepatic injury
history
hospital
Hospital admission
hospitalisation
hospitalised
hospitalised patient
Hospitalized
Hydroxychloroquine
Hypothesis
In-hospital
include
independent
Inpatient
intensive care
intensive care unit
International Conference
Intervention
intervention arm
Invasive mechanical ventilation
Laboratory
marker
Microbiology
Mortality
nasopharyngeal
NEWS2
non-invasive ventilation
Norway
number
Nurse
objective
open label
Oropharyngeal
Oropharyngeal sampling
outcome
oxygen
participant
Patient
patients
peptide
Placebo
polymerase chain
polymerase chain reaction
positive
Practice
Pragmatic
pragmatic trial
primary endpoint
profile
Prolonged
Protein
protocol
QT interval
randomisation
randomised
randomised controlled
randomised controlled trial
randomization
Randomized
Randomized controlled trial
recruited
recruitment
Registered
renal
requiring supplemental oxygen
resource
responsible
RT-PCR
Safe
Sample size
SARS-CoV-2
SARS-CoV-2 viral load
score
secondary
Seven
standard care
statistical analyses
status
Study protocol
subjects
Surveillance
therapy
transcriptase
Treatment
treatment allocation
Trial
Two-arm
university
use of hydroxychloroquine
Viral load
virological clearance
viruses
vital signs
website
[DOI] 10.1186/s13063-020-04420-0 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04420-0 PMC 바로가기 [Article Type] Letter
Estimates of the severity of coronavirus disease 2019: a model-based analysis
Article
[키워드] adjusted
age
aggregate
Analysis
attack rate
case fatality ratio
China
clinically
collected
coronavirus disease
COVID-19
COVID-19 disease
CrI
cumulative
death
diagnosed
died
discharge
distribution
estimate
estimates
fatality
finding
funding
Government
group
Health
Hong Kong
hospital
hospital discharge
hospitalisation
hospitalised
infected individual
Infection
International
Laboratory
Macau
magnitude
media
Medical Research Council
National
occurred
Older
Older age
onset of symptom
outcome
Patient
PCR-confirmed
Prevalence
produced
proportion
provincial health commission
reported
risk of death
robust
severity
stratified
subset
the mean
website
were used
[DOI] 10.1016/S1473-3099(20)30243-7 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/S1473-3099(20)30243-7 PMC 바로가기 [Article Type] Article